Natera (NTRA) has entered into a collaboration with NVIDIA (NVDA) aimed at accelerating the development of its multimodal AI foundation model platform to expand its applications in precision care. This partnership will leverage Natera’s extensive longitudinal in vivo datasets and existing machine learning models alongside NVIDIA’s advanced computing capabilities and AI tools.
The collaboration intends to establish robust computational frameworks essential for training large-scale AI models capable of processing complex medical data. Such advancements are expected to enhance diagnostic accuracy, improve disease understanding, and support customized treatment decisions for healthcare providers.
Natera is committed to building a robust computing foundation to deepen biological insights. By integrating its comprehensive dataset and AI expertise with NVIDIA’s high-performance computing resources, they anticipate the ability to train AI models on a significantly larger scale. NVIDIA highlighted that AI is revolutionizing precision medicine by facilitating quicker and more accurate biological research. This alliance is poised to enhance AI’s capacity to interpret diverse biological data, ultimately leading to more personalized testing and enriched treatment insights.
Following the announcement, Natera’s stock rose 0.5% by the end of the trading session. The company’s shares have surged approximately 48.9% over the past six months, compared to a 10.5% increase in the industry and a 14.1% rise in the S&P 500.
Ultimately, this collaboration strengthens Natera’s competitive position by enhancing its AI and data capabilities, which are critical for delivering precise, data-driven insights in precision healthcare and beyond. NVIDIA’s robust computing infrastructure and AI frameworks will bolster the effectiveness and scalability of Natera’s precision oncology solutions. The partnership opens pathways for the development of scalable AI models, creates opportunities for new revenue streams, and solidifies relationships with biopharma partners, all of which support sustained growth relative to competitors.
Natera currently boasts a market capitalization of $32.41 billion.
In addition to the NVIDIA partnership, Natera’s AI solutions are built upon one of the largest cancer datasets globally, aimed at addressing significant challenges in cancer treatment. The company’s NeoSelect system outperforms over 25 commonly used neoantigen prediction methodologies, while its NeoPredict has demonstrated more than double the improvement in immunotherapy response hazard ratios when compared to tumor mutational burden, the standard approach in current clinical settings.
To facilitate its initiatives, Natera plans to utilize several NVIDIA technologies. These include NVIDIA Parabricks for expediting bioinformatics workflows, NVIDIA BioNeMo for training large AI models, and the NVIDIA NeMo Agent Toolkit for developing AI systems for both clinical and research applications. Evidence suggests that Parabricks can reduce analysis time by approximately 75.7% and costs by about 59.2%, while NVIDIA’s Transformer Engine can enhance AI training speed by around 45.5%.
These technological advancements align with Natera’s objective of innovating sophisticated multimodal AI models capable of interpreting complex biological data types, identifying new drug targets, refining therapy response predictions, and discovering novel prognostic biomarkers. Interest from pharmaceutical companies has surged since the initial launch of its AI platform, contributing to expansion in Natera’s data business.
The oncology market for artificial intelligence is projected to be valued at $2.40 billion by 2026, with a compound annual growth rate (CAGR) of 27.6% anticipated through 2035, according to Precedence Research. This growth is driven by advancing technologies in healthcare, a rising incidence of cancer cases, and increasing demands for early cancer detection.
Natera has also recently announced a partnership with Exelixis, Inc. for the STELLAR-316 trial, a Phase 3 clinical study evaluating Exelixis’ new oral cancer treatment, zanzalintinib, both as a standalone and in combination with an immunotherapy agent. The trial will focus on patients with stage II or III colorectal cancer, post-surgical tumor removal.
Additionally, Natera introduced an enhanced version of its Fetal Focus non-invasive prenatal test, which evaluates 21 genes. Underpinned by results from the EXPAND trial, Fetal Focus achieved an overall accuracy rate of 96%, identifying 24 out of 25 affected pregnancies, and attained 98% accuracy in excluding unaffected cases from a total of 294 samples encompassing all 21 genes.
Currently, Natera carries a Zacks Rank #4 (Sell), while other notable stocks in the medical sector include Veracyte (VCYT) with a Zacks Rank #1 (Strong Buy), which reported third-quarter 2025 adjusted earnings per share of 51 cents, surpassing the Zacks Consensus Estimate by 59.4%. Veracyte’s revenues reached $131.8 million, exceeding expectations by 5.5%. Meanwhile, CareDx (CDNA), rated Zacks Rank #2 (Buy), reported a third-quarter adjusted EPS of 28 cents, surpassing the Zacks Consensus Estimate by 115.4% and achieving revenues of $100.1 million, also above expectations by 5.1%.
See also
Sam Altman Praises ChatGPT for Improved Em Dash Handling
AI Country Song Fails to Top Billboard Chart Amid Viral Buzz
GPT-5.1 and Claude 4.5 Sonnet Personality Showdown: A Comprehensive Test
Rethink Your Presentations with OnlyOffice: A Free PowerPoint Alternative
OpenAI Enhances ChatGPT with Em-Dash Personalization Feature
